ZORYVE™
(roflumilast) Cream 0.3%
FDA Approval Call
August 1, 2022
In light of the potential for data from our clinical trials to support a marketing application, as well as the timing of our product candidates; our ability to obtain and maintain regulatory approvals; the size and growth potential of the markets for our product(s) and product candidates; the timing of and our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Further information on these and other factors that could affect these forward-looking statements is contained in our our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 22, 2022, and other reports filed with the SEC from time to time.

You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our Industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Neither we nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

All product and company names are trademarks™ or registered® trademarks of their respective holders.
Today’s Speakers

Frank Watanabe
President & CEO

Patrick Burnett, MD, PhD, FAAD
Chief Medical Officer

Ken Lock
Chief Commercial Officer
Speakers & Agenda

Arcutis Overview

ZORYVE - Differentiated Clinical Profile
Commercial Execution
Conclusions
Q&A
2022: A Transformational Year for Arcutis Continues

- FDA approval of ZORYVE (roflumilast) in plaque psoriasis and imminent launch is the realization of our efforts to bring meaningful innovation to address the unmet needs of patients with immune-mediated skin diseases.

- Topical roflumilast is a unique “pipeline-in-a-product” opportunity across four development programs.

- We remain confident in continuing our track record of Phase 3 successes in subsequent pivotal readouts in atopic dermatitis and scalp and body psoriasis later this year.

- We will further strengthen our balance sheet by drawing an additional $125 million from our debt facility; enables robust launch investment for ZORYVE and continued pipeline advancement.
Strategic Milestone Today with Our Transition to Commercial-Stage Immuno-Dermatology Company

**Filling the innovation gap**
in the dermatology drug sector

**Elevating the standard of care**
to simplify disease management and optimize drug efficacy, safety, and tolerability

**Developing potential best-in-class**
and innovative topical dermatology therapies against validated biological targets

**World-class leadership team**
>50 FDA-approved products

**Rapidly advancing**
a broad, innovative pipeline with strong IP protection for clinical assets

*FDA = U.S. Food and Drug Administration; IP = intellectual property*
~7 million Dermatologist-Treated Patients Could Benefit From Topical Roflumilast in the U.S. Alone

<table>
<thead>
<tr>
<th></th>
<th>Psoriasis</th>
<th>Atopic Dermatitis</th>
<th>Seborrheic Dermatitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalence</td>
<td>~9M</td>
<td>~26M</td>
<td>~10M</td>
</tr>
<tr>
<td>Topical Rx treated in Derm setting</td>
<td>~2.0M (mild-moderate-severe)</td>
<td>~2.6M (mild-to-moderate)</td>
<td>~2.2M (moderate-to-severe)</td>
</tr>
<tr>
<td>Topically treated outside Derm</td>
<td>~1.2M (mild-moderate-severe)</td>
<td>~4.1M (mild-to-moderate)</td>
<td>~1.0M (moderate-to-severe)</td>
</tr>
</tbody>
</table>

Significant incremental opportunity to access the millions of U.S. patients Rx treated by other specialties (e.g., PCPs or pediatricians) via partnership

Rx = Prescription; PCP = primary care physician
ZORYVE (zor-eev) - Next Generation PDE4 Inhibitor Approved for Treatment of Plaque Psoriasis in Ages 12+

Established, rapid efficacy
Significant clearance of plaques + itch in all affected areas of the body

Uniquely broad label
Once-daily treatment in mild, moderate, & severe plaque psoriasis, *including intertriginous psoriasis*

Very well-tolerated, steroid-free cream
Minimal adverse application site reactions; coupled with our proprietary HydroARQ™ technology

Efficacy & safety suitable for long-term use
No boxed warnings/limitations on duration of use

PDE4 = phosphodiesterase-4
Speakers & Agenda

Arcutis Overview

ZORYVE - Differentiated Clinical Profile

Commercial Execution

Conclusions

Q&A

Patrick Burnett, MD, PhD, FAAD
Chief Medical Officer
Plaque Psoriasis – Significant Unmet Needs in Treatment Paradigm

~9M individuals in the U.S. affected\(^1\)

>90% of U.S. patients treated with topical drugs\(^1\)

Past topical therapies have numerous shortcomings

Physicians and patients forced to trade-off between efficacy and safety/tolerability

81% Of patients wish they had more topical treatment alternatives to steroids\(^2\)

---

\(^1\) 2021 Decision Resources Group (Psoriasis Landscape and Forecast + Psoriasis Epidemiology) reports; \(^2\) Skin Insights: Uncovering Psoriasis survey of >500 adults who use topicals, March 2022
ZORYVE Cream – FDA-Approved U.S. Label in Psoriasis

Once-daily treatment in mild, moderate, & severe plaque psoriasis

- Indication for treatment of intertriginous areas
- Indication for ages 12+
- Itch data (WI-NRS) included in label

WI-NRS: Worst Itch Numeric Rating Scale

ZORYVE™ (roflumilast) cream 0.3%
Rapid, Robust Efficacy on IGA Success in Both Phase 3 Plaque Psoriasis Trials

IGA = Investigator's Global Assessment; IGA Success = Clear or Almost Clear with at least a 2-grade improvement from baseline; ITT Population
Statistical analysis based on multiple imputation; Week 2, 4, and 6 consistent with label

[Bar charts showing IGA Success at Week 2, 4, 6, and 8 for ZORYVE Cream 0.3% and Vehicle groups for DERMIS-1 and DERMIS-2 trials.]
Significant and Rapid Clearance of Plaques in DERMIS Phase 3 Trials

Baseline (Heel)  Week 4  Week 8

IGA = 2  IGA = 0  IGA = 0

Demonstrated efficacy in tough-to-treat areas (knees/elbows) + intertriginous/sensitive areas

Individual patient results may vary
Demonstrated Efficacy and Favorable Safety and Tolerability in Treating Intertriginous Plaques

I-IGA Success = Clear or Almost Clear with at least a 2-grade improvement from baseline

Survey Suggests ~2 in 3 Patients Have Exhibited Psoriasis in Intertriginous Areas

*P<0.01; **P<0.001; ***P<=0.0001;  I-IGA-intent-to-treat population: patients with intertriginous area involvement with severity of the intertriginous lesions at least mild (I-IGA ≥2) at baseline. Statistical analysis based on multiple imputation; Week 2, 4, and 6 consistent with label; I-IGA, Intertriginous-Investigator's Global Assessment. 1Skin Insights: Uncovering Psoriasis survey of >500 adults who use topicals, March 2022
Rapid Reduction of Itch in DERMIS-1 and DERMIS-2

Proportion of patients who achieved a ≥4-point improvement in WI-NRS from baseline score of ≥4

Robust reduction in itch occurs early and consistently improves through Week 8

*P <0.001; ** P <0.0001; Evaluated in a subset of the intent-to-treat population of patients with WI-NRS pruritus score ≥4 at baseline; WI-NRS: Worst Itch Numeric Rating Scale

Statistical analysis based on multiple imputation
# ZORYVE – Safe and Very Well-Tolerated

<table>
<thead>
<tr>
<th>Adverse Reactions Reported in &gt;=1% of Subjects for 8 Weeks [n (%)]</th>
<th>ZORYVE (n=576)</th>
<th>Vehicle (n=305)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea</td>
<td>18 (3.1)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Headache</td>
<td>14 (2.4)</td>
<td>3 (1.0)</td>
</tr>
<tr>
<td>Insomnia</td>
<td>8 (1.4)</td>
<td>2 (0.7)</td>
</tr>
<tr>
<td>Nausea</td>
<td>7 (1.2)</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Application site pain</td>
<td>6 (1.0)</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>6 (1.0)</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>6 (1.0)</td>
<td>2 (0.7)</td>
</tr>
</tbody>
</table>

Data are presented for safety population.
Durability of Response Maintained: Phase 2 Long-Term Data in Plaque Psoriasis

In 594 subjects who continued ZORYVE for up to 64 weeks in OLE trials, the adverse reaction profile was similar to that of vehicle-controlled trials.

- **Durable efficacy over 52–64 weeks**
  - Comparable to DERMIS-1/2 8-week efficacy
  - Median duration of IGA of Clear or Almost Clear = 37 weeks

- **73.5% of patients completed 52–64 weeks of treatment**
  - Only 0.9% discontinued due to lack of efficacy
  - Only 3.9% discontinued due to any adverse event

**IGA of ‘Clear’ or ‘Almost Clear’**

- **ZORYVE Cream 0.3% (201→202)**
- **ZORYVE Cream 0.3% after Vehicle Crossover (201→202)**

Observed data from ARQ-151-202 study; IGA = Investigator’s Global Assessment; OLE = open label extension
Speakers & Agenda

Arcutis Overview
ZORYVE - Differentiated Clinical Profile
Commercial Execution
Conclusions
Q&A

Ken Lock
Chief Commercial Officer
ZORYVE: Designed to Simplify the Treatment of Psoriasis
# ZORYVE Cream’s Label in Psoriasis is Recognition of Our Differentiated Profile

<table>
<thead>
<tr>
<th>In Label</th>
<th>DUOBRII®</th>
<th>ENSTILAR®</th>
<th>Wynzora®</th>
<th>VTAMA™</th>
<th>ZORYVE™</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intertriginous efficacy</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>+</td>
</tr>
<tr>
<td>Approved down to age 12</td>
<td>—</td>
<td>✔️</td>
<td>—</td>
<td>—</td>
<td>+</td>
</tr>
<tr>
<td>Itch efficacy data</td>
<td>—</td>
<td>—</td>
<td>✔️</td>
<td>—</td>
<td>+</td>
</tr>
<tr>
<td>Lack of warnings or precautions</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>✔️</td>
<td>+</td>
</tr>
<tr>
<td>No limitations on duration of use</td>
<td>✔️</td>
<td>—</td>
<td>—</td>
<td>✔️</td>
<td>+</td>
</tr>
</tbody>
</table>

Comparison based on FDA-approved labels for referenced products. No head-to-head trials between these products have been conducted.

DUOBRII®: halobetasol propionate and tazarotene; ENSTILAR®: calcipotriene and betamethasone dipropionate; Wynzora®: calcipotriene and betamethasone dipropionate; VTAMA™: tapinarof

©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience.
ZORYVE - Patient-Friendly Formulation That Effectively Delivers Highly Potent PDE4

- Once-daily dosing
- Steroid-free
- Uniquely featuring HydroARQ Technology
  - Non-greasy, moisturizing cream
  - Spreads easily, absorbs quickly
  - No sensitizing excipients or irritants (e.g. propylene glycol, ethanol)
Patient Dynamics Are Favorable Towards Trial

~2M
Psoriasis patients currently Rx treated topically by U.S. dermatologists

Minimal behavioral change required to activate utilization
• 90% of U.S. patients treated with topicals

Highly dynamic market facilitates start/switch
• Steroids limited to short duration – frequent need to switch

Sparse competitive landscape for innovative topical therapies
• Synergy in activating non-steroidal market with two innovative topicals launching
## Strong Patient Interest and Engagement in Innovation

<table>
<thead>
<tr>
<th>Patients</th>
<th>Wish there were more effective topical treatment options</th>
<th>Wish topical treatments were a once daily application</th>
<th>Wish they could use a single topical therapy anywhere on their body</th>
<th>Are interested in trying a new topical treatment for their psoriasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 in 10 Patients</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

2 in 3 Patients have exhibited psoriasis in intertriginous areas

9 in 10 Intertriginous patients would be more adherent if a single topical could be used everywhere on the body

Source: Skin Insights: Uncovering Psoriasis survey of >500 adults who use topicals, March 2022
Our Access Strategy Remains Unchanged: Unlocking Broad, High-Quality Access to ZORYVE

**Responsible pricing**

Designed to obtain broad and rapid coverage

**Reduced prescriber burden**

Key to maximizing volume opportunity

**Rapid follow-on indications**

Allow for portfolio volumes across multiple indications
WAC Price of $825 Optimizes for Our Access Objectives, Helps More Patients, & Maximizes Total Franchise Value

**Our Access/Coverage Goals**
- High-quality coverage for patients
- Faster formulary consideration/adoptions
- Preservation of gross-to-net
- Optimizing for volume & franchise value

**Topical Roflumilast**
- Highly innovative
- Effective, safe, well-tolerated
- Potential 1st line treatment option
- Potential follow-on indications in AD & Seb Derm with varied patient mix

$825/tube

©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience.
List Prices of Select Branded Topicals

Source: Analysource – 7/15/22; CMS = Centers for Medicare & Medicaid Services
Patients will be supported via ZORYVE Direct

Savings Program*

<table>
<thead>
<tr>
<th>Commercially insured patients with ZORYVE coverage</th>
<th>Commercially insured patients without ZORYVE coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>$25</td>
<td>$75</td>
</tr>
</tbody>
</table>

For financially eligible patients who are uninsured or underinsured, Arcutis will also offer the Arcutis Cares™ patient assistance program.

*Uninsured patients and patients with government insurance are not eligible for the ZORYVE Direct savings program; other terms and restrictions apply.
ZORYVE Launch Readiness

- Sales force fully hired; detailing begins today
- Product expected in channel in < 2 weeks
- Broad sampling program ready to activate
- ZORYVE Direct patient support active
Speakers & Agenda

Frank Watanabe
President and CEO

Arcutis Overview
ZORYVE – Differentiated Clinical Profile
Commercial Execution

Conclusions

Q&A
Continued Execution Against Our Four Transformational Catalysts in 2022

- **Q2 2022**: Seborrheic Dermatitis
  - Phase 3 – Topline Data

- **Q3 2022**: Plaque Psoriasis
  - FDA Approval

- **Q4 2022**: Scalp Psoriasis
  - Phase 3 – Expected Topline Data

- **Atopic Dermatitis**
  - Phase 3 – Expected Topline Data*

* Phase 3 topline for INTEGUMENT-1 and -2; INTEGUMENT-PED expected in 2023

Roflumilast Cream  |  Roflumilast Foam
2022: A Transformational Year for Arcutis Continues

FDA approval of ZORYVE (roflumilast) in plaque psoriasis and imminent launch is the realization of our efforts to bring meaningful innovation to address the unmet needs of patients with immune-mediated skin diseases.

Topical roflumilast is a unique “pipeline-in-a-product” opportunity across four development programs.

We remain confident in continuing our track record of Phase 3 successes in subsequent pivotal readouts in atopic dermatitis and scalp and body psoriasis later this year.

We will further strengthen our balance sheet by drawing an additional $125 million from our debt facility; enables robust launch investment for ZORYVE and continued pipeline advancement.
Thank You

Arcutis Overview
ZORYVE – Differentiated Clinical Profile
Commercial Execution
Conclusions

Q&A

Frank Watanabe
President and CEO

Scott Burrows
Chief Financial Officer

Patrick Burnett, MD, PhD, FAAD
Chief Medical Officer

Ken Lock
Chief Commercial Officer